Clinical trials: Atopic Disease
Dermatitis, Atopic
Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis
This study is being conducted to characterize the mechanism of action of crisaborole ointment 2%, by evaluation of efficacy and changes in key skin biomarkers in atopic dermatitis (AD) lesions treated with crisaborole ointment 2%…
- Trial name
- NCT03233529
- Testing
- Crisaborole ointment 2% BID
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Pfizer
Asthma
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks.
- Trial name
- NCT00079937
- Testing
- Omalizumab, Fluticasone
- Where
- 56 sites in United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients
This extension study (CZPL389A2203E1) was designed as a 2-year (100 weeks) extension to the core study (CZPL389A2203/ NCT03517566) which is disclosed separately.
- Trial name
- ZESTExt (NCT03948334)
- Testing
- ZPL389 30mg, ZPL389 50mg, TCS and/or TCI
- Where
- 48 sites in United States, Belgium and 11 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis, Skin Diseases
Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)
This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT05469464
- Testing
- Orismilast modified release tablets
- Where
- 48 sites in United States, Germany and 2 more
- Volunteers
- 235 people
- Sponsor
- UNION therapeutics
Eczema
A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin
This study is for infants with mild to moderate dry and itchy skin. This study will involve going to the doctor for 6 visits over 2 weeks.
- Trial name
- NCT02120833
- Testing
- EpiCeram® Skin Barrier Emulsion, Colloidal Oatmeal Cream
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Atopic Dermatitis
Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis
This study will assess the safety, tolerability, and efficacy of Alefacept in patient with moderate to severe atopic dermatitis who could not be adequately controlled with topical therapies.
- Trial name
- NCT00832585
- Testing
- Alefacept
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Rush University Medical Center
Asthma
Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
Primary purpose of the protocol is to determine if IMA-638 prevents a mild asthma attack by a subject with mild asthma inhaling an allergen.
- Trial name
- NCT00410280
- Testing
- IMA-638 is a biologic
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Pfizer
Asthma
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
The purpose of the study was to assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose Inhaled Corticosteroid (ICS) as background therapy.
- Trial name
- NCT01836471
- Testing
- QAW039, Fluticasone 250 mcg, Fluticasone 100 mcg
- Where
- 76 sites in United States, Belgium and 8 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT04033367
- Testing
- Dupilumab
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 188 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT03747575
- Testing
- MSTT1041A
- Where
- 21 sites in United States, Germany and 1 more
- Volunteers
- 65 people
- Sponsor
- Genentech, Inc.
Dermatitis, Atopic
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
The primary objective of this study is to characterize the safety and tolerability of MK-6194 following multiple doses among participants with moderate to severe atopic dermatitis who are unresponsive to other therapies.
- Trial name
- NCT05450198
- Testing
- MK-6194
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 72 people
- Sponsor
- Merck Sharp & Dohme LLC
Atopic Dermatitis
Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens
AD is a disease found in children; the focus of the study is the mechanisms associated in children with AD induced by food allergies.
- Trial name
- NCT00557284
- Testing
- Montelukast
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- 1st Allergy & Clinical Research Center
Dermatitis, Atopic
An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of VTP-38543 administered as a cream, twice-daily, for 28 days in otherwise healthy adult…
- Trial name
- NCT02655679
- Testing
- VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P
- Where
- 12 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- Vitae Pharmaceuticals, Inc.
Allergic Conjunctivitis
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
To compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects.
- Trial name
- NCT05815758
- Testing
- Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
- Where
- 7 sites in United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Atopic Dermatitis
Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis
To establish the bioequivalence between test drug, Pimecrolimus Cream, 1% with that of reference listed drug, Elidel® (pimecrolimus) Cream 1%, in the treatment of mild to moderate Atopic Dermatitis.
- Trial name
- NCT03107611
- Testing
- Pimecrolimus Cream, 1%
- Where
- 27 sites in United States, Dominican Republic and 1 more
- Volunteers
- 654 people
- Sponsor
- Mylan Inc.
Atopic Dermatitis
A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis
The purpose of this study is to investigate the effectiveness and safety of 2 concentrations of OPA-15406 compared to vehicle in participants with atopic dermatitis (AD).
- Trial name
- NCT02068352
- Testing
- OPA-15406, Vehicle ointment
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 121 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Atopic Dermatitis
A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis
The purpose of this research study is to better understand how fluocinonide cream 0.1% (Vanos®) works when people use it to treat atopic dermatitis for just a few days.
- Trial name
- Vanos (NCT01049243)
- Testing
- Fluocinonide Cream 0.1%
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Atopic Dermatitis
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.
- Trial name
- NCT06101823
- Testing
- OpSCF
- Where
- 22 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Insmed Incorporated
Atopic Dermatitis
Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis
Atopic dermatitis (AD) is a chronic disease associated with intense itching, which affects most aspects of everyday life in the majority of patients.
- Trial name
- NCT01806662
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Rockefeller University
Atopic Dermatitis
A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis
This study will evaluate crisaborole therapy once daily (QD) as a long-term topical maintenance therapy for the reduction of flare in responders to crisaborole twice daily (BID) treatment.
- Trial name
- NCT04040192
- Testing
- Crisaborole 2%, Vehicle
- Where
- 44 sites in United States, Australia and 4 more
- Volunteers
- 620 people
- Sponsor
- Pfizer